Evidence map›Paper›PMID 26604914›Full record

ArticleNeural regeneration research2015

Stem Cell Ophthalmology Treatment Study (SCOTS) for retinal and optic nerve diseases: a case report of improvement in relapsing auto-immune optic neuropathy.

Jeffrey N Weiss, Steven Levy, Susan C Benes

2 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neural regeneration research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01920867 naunknown statusnot on this map

Bone Marrow Derived Stem Cell Ophthalmology Treatment Study

TypeinterventionalSponsorMD Stem CellsRan2012 to 2020Enrolled300ConditionsRetinal Disease, Macular Degeneration, Hereditary Retinal Dystrophy, Optic Nerve DiseaseArmsRB (Retrobulbar), ST (Subtenon), IV (Intravenous), IVIT (Intravitreal), IO (Intraocular)
NCT03011541 narecruitingnot on this mapstarted 2016, after this paper: background citation

Bone Marrow Derived Stem Cell Ophthalmology Treatment Study II

TypeinterventionalSponsorMD Stem CellsRan2016 to 2028Enrolled500ConditionsRetinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt DiseaseArmsArm 1
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Peripheral nerve repair: innovations and future directions.Journal of translational medicine · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Cells · 2024
    Article
  8. Regenerative mechanisms of stem cells and their clinical applications for degenerative eye diseases.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2024
    Review
  9. Evaluation of mesenchymal stem cells as anFrontiers in cell and developmental biology · 2024
    Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Stem cell therapies for retinal diseases: from bench to bedside.Journal of molecular medicine (Berlin, Germany) · 2020
    Review
  16. Review
  17. Article
  18. Article
  19. Retinal stem cell transplantation: Balancing safety and potential.Progress in retinal and eye research · 2020
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jeffrey N WeissRetina Associates of South Florida, Margate, FL, USA.
Steven LevyMD Stem Cells, Ridgefield, CT, USA.ORCID 0000-0002-9313-3448
Susan C BenesWilmer Eye Institute, The Johns Hopkins Hospital, Baltimore, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present the results from a patient with relapsing optic neuropathy treated within the Stem Cell Ophthalmology Treatment Study (SCOTS). SCOTS is an Institutional Review Board approved clinical trial and has become the largest ophthalmology stem cell study registered at the National Institutes of Health to date (www.clinicaltrials.gov Identifier NCT 01920867). SCOTS utilizes autologous bone marrow-derived stem cells (BMSCs) for treatment of retinal and optic nerve diseases. Pre-treatment and post-treatment comprehensive eye exams of a 54 year old female patient were performed both at the Florida Study Center, USA and at The Eye Center of Columbus, USA. As a consequence of a relapsing optic neuritis, the patient's previously normal visual acuity decreased to between 20/350 and 20/400 in the right eye and to 20/70 in the left eye. Significant visual field loss developed bilaterally. The patient underwent a right eye vitrectomy with injection of BMSCs into the optic nerve of the right eyeand retrobulbar, subtenon and intravitreal injection of BMSCs in the left eye. At 15 months after SCOTS treatment, the patient's visual acuity had improved to 20/150 in the right eye and 20/20 in the left eye. Bilateral visual fields improved markedly. Both macular thickness and fast retinal nerve fiber layer thickness were maximally improved at 3 and 6 months after SCOTS treatment. The patient also reduced her mycophenylate dose from 1,500 mg per day to 500 mg per day and required no steroid pulse therapy during the 15-month follow up.

Indexed as

autoimmuneblindnessbone marrow-derived stem cellsnerve regenerationneural regenerationophthalmologyoptic nerveoptic neuropathyStem Cell Ophthalmology Treatment Studystem cellsvisual loss

Identifiers

PMID26604914
PMCPMC4625519

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.